Brussels shares TFN market data at 10.09 am; Agfa-Gevaert tumbles

Brussels shares TFN market data at 10.09 am; Agfa-Gevaert tumbles

	Published : Thu, 18 Oct 2007 09:34 By : Agencies Print this Story

BRUSSELS (Thomson Financial) - Brussels shares TFN market data at 10.09 am:

Main index

-Bel 20 down 19.12 points or 0.42 pct at 4,487.28

Bel 20 fallers

-Agfa-Gevaert tumbles 2.27 eur or 16.57 pct to 11.43 on profit warning, KBC lowers target price to 12 eur from 15.80, maintains are duce' rating, share price dropped to lowest level since November 2001

-Umicore drops 3.81 eur or 2.11 pct to 176.64

-Inbev drops 0.74 eur or 1.11 pct to 65.66 after yesterday's gains, triggered by news that peers Carlsberg and Heineken may form a consortium to acquire Scottish & Newcastle and renewed rumours of Inbev tie-up with Anheuser-Busch

Bel 20 gainers

-Solvay gains 1.24 eur or 1.22 pct to 103.28

-Bekaert up 0.70 eur or 0.70 pct at 100.47

-Belgacom rises 0.16 eur or 0.48 pct to 33.29 as investors anticipate news on interim dividend seen at 0.32 eur

-Delhaize 0.29 eur or 0.43 pct higher at 68.02, opens fourth store in Germany

Outside the Bel 20

-Innogenetics up 0.06 eur or 0.99 pct at 6.12, signed a licensing agreement with Swiss peer Novartis AG in the field of hepatitis C Virus (HCV) diagnostics, no financial details disclosed

-Oncomethylome Sciences up 0.21 eur or 2.10 pct at 10.20. EXACT Sciences, with which OncoMethylome has a collaboration in stool-based colorectal

cancer testing, has received a letter from the FDA regarding regulatory matters related to its DNA technology for colorectal cancer screening. The FDA believes that the PreGen-Plus assay is a medical device requiring premarket approval or clearance. ING says timing of the news is 'unfortunate', just one day after the group's 10.6 mln eur secondary placing at 10 eur per share

-Deceuninck edges 0.01 eur or 0.05 pct higher to 18.75, plans to restructure German subsidiary Inoutic/Deceuninck GmbH

antonia.vandevelde@thomson.com

ava/cmr

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.